EDGE Insights

EDGE Insights

icon
Filter
Older updates:
Livestock Biotech

Livestock Biotech

Gene Editing (Non-Human)

The following report was prepared and published by our sister platform SPEEDA—March 2024.

Trend Overview

CRISPR-Cas9 Enabled Commercialisation of Gene Editing with Higher Accuracy, Efficiency, and Cost-Effectiveness Than Traditional GMO Techniques

Gene editing is a technique that enables scientists to add, remove, or alter genetic material (DNA) at specific locations in the genome (the complete set of genes). This can be done on any DNA sequence in a bacterium, plant, animal, or human. This report mainly focuses on gene editing of non-human organisms such as plants and animals.
Gene editing has been around since the late 1900s. However, it remained out of reach for commercial usage due to a lack of advancements in gene editing tools. The possibility of using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-Cas9) for gene editing was identified in 2012. Compared to its predecessors, Zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), CRISPR-Cas9 can be easily designed with low cost, has higher efficiency, is easier to use, and enables multiple gene edits (multiplexing) simultaneously.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.